Skip to Content
Merck
  • [Clinical research of early, enough methylprednisone combined with immunoglobulin in treatment of severe hand-foot-mouth disease].

[Clinical research of early, enough methylprednisone combined with immunoglobulin in treatment of severe hand-foot-mouth disease].

Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology (2014-03-22)
Ming Jiang, Xing-Chuan Wang
ABSTRACT

To study the efficacy of early, enough methylprednisone combined with immunoglobulin in treatments of severe hand-foot-mouth disease. 568 patients of severe hand-foot-mouth disease involved were randomized into group A and group B. Patients of both groups all accepted symptomatic treatment, supportive therapy and the treatment of control intracranial pressure. And patients in group A received the treatment of early, enough methylprednisone combined with immunoglobulin, whereas patients in group B received conventional therapy. RESULTS; Curative rate of group A was better than that of group B, otherwise incidence rate of critical illness was less than that of group B. The control time of fever, erythra, neurological symptoms, features of pneumonia and increased leukocyte of group A was shorter than that of group B, and no more recent or Long-term treatment-related adverse reaction in group A. Early, enough methylprednisone combined with immunoglobulin is effective, safe in treating severe hand-foot-mouth disease, and worthy to recommand its clinical use.

MATERIALS
Product Number
Brand
Product Description

USP
Methylprednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard
Methylprednisolone hydrogen succinate for performance test, European Pharmacopoeia (EP) Reference Standard
Methylprednisolone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard